Dendrimer based nanodevices for therapeutic and imaging purposes
A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.
1. A nanodevice composition comprising N-acetyl cysteine linked to a PAMAM dendrimer via disulfide bonds.
2. The nanodevice according to claim 1 , wherein said PAMAM dendrimer is selected from the group consisting essentially of G4-PAMAM-NH2, G4-PAMAM-COOH, and G4-PAMAM-OH.
3. A nanodevice composition comprising N-acetyl cystine linked to a PAMAM dendrimer via one or more spacer compounds selected from the group consisting essentially of SPDP, Glutathione (GSH), Gamma-aminobutyric acid (GABA), and combination thereof.
4. A nanodevice for targeted delivery of a compound to a location in need of treatment, said nanodevice comprising a PAMAM dendrimer linked to the compound via a disulfide bond.
5. The nanodevice according to claim 4 , wherein said compound is an anti-inflammatory agent.
6. The nanodevice according to claim 4 , wherein said PAMAM dendrimer is selected from the group consisting essentially of G4-PAMAM-NH2, G4-PAMAM-COOH, and G4-PAMAM-OH.
7. The nanodevice according to claim 4 , further including one or more spacer compounds linked between N-acetyl-cysteine and said PAMAM dendrimer.
8. The nanodevice according to claim 7 , wherein said spacer includes at least one spacer selected from the group consisting essentially of SPDP, Glutathione (GSH), Gamma-aminobutyric acid (GABA), and combinations thereof.
9. The nanodevice according to claim 4 , wherein said compound is capable of localizing and targeting microglia and astrocytes.
10. The nanodevice according to claim 4 , wherein said compound is a drug needed to be delivered across a blood-brain-barrier.
11. The nanodevice according to claim 10 , wherein said drug is a drug for treating cerebral palsy.
12. The nanodevice according to claim 10 , wherein said drug is a drug for treating neuroinflammation.
13. A nanodevice composition for localizing and delivering therapeutically active agents, said nanodevice comprising: a PAMAM dendrimer; and at least one therapeutically active agent attached to said PAMAM dendrimer via disulfide bonds, wherein said at least one therapeutically active agent comprises N-acetyl cysteine.
14. The nanodevice according to claim 13 , wherein said PAMAM dendrimer is selected from the group consisting essentially of G4-PAMAM-NH2, G4-PAMAM-COOH, and G4-PAMAM-OH.
15. A nanodevice composition for localizing and delivering therapeutically active agents, said nanodevice comprising: a PAMAM dendrimer; and at least one therapeutically active agent attached to said PAMAM dendrimer via one or more spacer compounds selected from the group consisting essentially of SPDP, Glutathione (GSH), Gamma-aminobutyric acid (GABA), amino acids, and combinations thereof, wherein said at least one therapeutically active agent comprises N-acetyl cysteine.
16. The nanodevice of claim 15 , wherein said nanodevice is administered in a manner selected from the group consisting essentially of parenteral, oral, and topical delivery systems.
17. The nanodevice according to claim 13 , wherein said nanodevice is capable of targeting and/or rapidly releasing or delivering said therapeutically active agent at the site of action or absorption either intracellularly or in interstitial spaces.
18. The nanodevice according to claim 13 , wherein said nanodevice includes a therapeutically active agent for localizing and targeting microglia and astrocytes.
19. The nanodevice according to claim 13 , wherein said therapeutically active agent is a drug needed to be delivered across a blood-brain-barrier.
20. The nanodevice according to claim 19 , wherein said drug is a drug for treating cerebral palsy.
21. The nanodevice according to claim 19 , wherein said drug is a drug for treating neuroinflammation.